Modularity Enhances Flexibility
“We continue to see growth in both the stainless steel and single-use markets, with increasing interest in biologicals, especially from biotech companies in China and India,” says Doru Felezeu, director of marketing and business development at Pierre Guerin Technologies. He also notes that “interesting applications are developing in green biotech along with a demand for reactors suitable for producing algae and biomass.”
To satisfy market demand for greater flexibility and modular system design, Pierre Guerin, through its Biolafitte division, introduced the TRYTONi™ series of open-design, modular, autoclavable bioreactors that can be used for cell culture or microbial fermentation.
This industrial version of the company’s TRYTON series of bioreactors is scalable from 1 L to 50,000 L. It is also waterproof and features a touchscreen user interface. Users can add or remove individual modules to customize the system for more or less complex operations. A key focus at Pierre Guerin over the next six months will be on the development of new software tools for process control.
In June, Xcellerex began construction of a new biomanufacturing facility at its Marlborough, MA, headquarters to expand its contract services operations. This is the company’s second facility that will house its FlexFactory® modular single-use bioprocess manufacturing platform, in which unit operations are self-contained in their own controlled environment modules, eliminating the need for cleanroom facilities.
Xcellerex and Pfenex announced in May that, together with their collaborators, they had demonstrated the capability to produce purified swine flu H1 hemagglutinin in 42 days, starting with the protein’s amino acid sequence. For this 24-month project funded by U.S. government defense agencies, Xcellerex contributed its microbial PDMax™ high-speed process-development system and its FlexFactory single-use manufacturing technologies to grow microbial production strains to high cell densities and to purify model vaccine and antibody molecules.
Earlier this year, Xcellerex announced a collaboration with Humacyte to develop a manufacturing process for Humacyte’s lead regenerative medicine product—vascular grafts for transplantation—using Xcellerex’ XDR™ single-use bioreactor system on the FlexFactory platform.
In development at Xcellerex is a redesign of the 50 L single-use vessel for the XDR system. The company has completed conversion of its 200 L, 500 L, 1,000 L, and 2,000 L vessels to a modular design. “This gives users more flexibility to locate the vessel remotely from the control system,” says Clapp.
Xcellerex also completed a redesign of its controlled environment modules to support upstream and downstream unit operations in the FlexFactory, incorporating a modular design for ease of scale-up and added capabilities to control chromatography, filtration, seed reactors, and bulk handling of the biological products. Also, the new control module is more readily compatible with plant-wide data-management systems to facilitate the flow of manufacturing and process data.
The primary local controller used to operate the XDR bioreactors is based on a Rockwell Automation platform, coupled with Wonderware human/machine interface software to support GMP operations with a server class computer, RAID, and built-in redundancy for improved protection of manufacturing data. For companies that utilize an Emerson DeltaV automation platform, Xcellerex offers the comparable functionality available with the Rockwell-Wonderware control system, allowing companies to integrate Xcellerex process equipment into their existing infrastructure.